- Home
- EAF vs SLP Comparison
EAF vs SLP Comparison
Compare EAF & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EAF
- SLP
- Stock Information
- Founded
- EAF 1886
- SLP 1996
- Country
- EAF United States
- SLP United States
- Employees
- EAF N/A
- SLP N/A
- Industry
- EAF Industrial Machinery/Components
- SLP EDP Services
- Sector
- EAF Energy
- SLP Technology
- Exchange
- EAF Nasdaq
- SLP Nasdaq
- Market Cap
- EAF 238.5M
- SLP 282.4M
- IPO Year
- EAF 1995
- SLP 1997
- Fundamental
- Price
- EAF $9.92
- SLP $13.84
- Analyst Decision
- EAF Hold
- SLP Buy
- Analyst Count
- EAF 6
- SLP 7
- Target Price
- EAF $17.00
- SLP $29.50
- AVG Volume (30 Days)
- EAF 217.2K
- SLP 360.6K
- Earning Date
- EAF 07-25-2025
- SLP 10-22-2025
- Dividend Yield
- EAF N/A
- SLP N/A
- EPS Growth
- EAF N/A
- SLP N/A
- EPS
- EAF N/A
- SLP N/A
- Revenue
- EAF $508,550,000.00
- SLP $80,383,000.00
- Revenue This Year
- EAF N/A
- SLP $12.75
- Revenue Next Year
- EAF $19.47
- SLP $3.06
- P/E Ratio
- EAF N/A
- SLP N/A
- Revenue Growth
- EAF N/A
- SLP 20.01
- 52 Week Low
- EAF $5.50
- SLP $12.39
- 52 Week High
- EAF $25.30
- SLP $37.67
- Technical
- Relative Strength Index (RSI)
- EAF 43.00
- SLP 43.15
- Support Level
- EAF $8.97
- SLP $13.93
- Resistance Level
- EAF $10.75
- SLP $14.52
- Average True Range (ATR)
- EAF 0.84
- SLP 0.50
- MACD
- EAF -0.11
- SLP 0.10
- Stochastic Oscillator
- EAF 23.00
- SLP 11.86
About EAF GrafTech International Ltd.
GrafTech International Ltd is a manufacturer of high-quality graphite electrode products essential to the production of EAF steel and other ferrous and non-ferrous metals. The company has only reportable segment, Industrial Materials, is comprised of its two product categories: graphite electrodes and petroleum needle coke products. Petroleum needle coke is key raw material used in the production of graphite electrodes.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.